<DOC>
	<DOCNO>NCT00319514</DOCNO>
	<brief_summary>To evaluate toxicity efficacy docetaxel cisplatin combination two schedule patient previously untreated , advanced NSCLC .</brief_summary>
	<brief_title>Weekly Versus 3-Weekly Docetaxel Plus Cisplatin Advanced NSCLC</brief_title>
	<detailed_description>The combination docetaxel 75 mg/m2 cisplatin 60-80 mg/m2 administer every 3 week one commonly use chemotherapy regimen Korea first-line treatment advance NSCLC . Although 3-weekly regimen active tolerate , associate significant incidence severe neutropenia , often complicate fever . Therefore , increase interest use weekly administration docetaxel way reduce hematologic toxicity . We design randomize phase II trial evaluate safety profile antitumor activity two different schedule docetaxel plus cisplatin give first-line therapy patient advance NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically cytologically proven nonsmall cell lung cancer prior chemotherapy adjuvant chemotherapy complete &gt; 6 month registration ECOG performance status 0 2 measurable lesion ( ) normal marrow , hepatic renal function provision write informed consent active infection severe comorbidities history anaphylaxis origin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>